---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-042630"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:21:28.311240+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tectonic reports Q4 2024 net loss $12.4M; positive TX45 Phase 1b interim results

## Summary
- TX45 Phase 1b Part A reduced PCWP by 17.9% in PH-HFpEF and PVR >30% in CpcPH subgroup.
- Completed ~$185.0M private placement in Feb 2025; cash runway into Q4'28.
- Cash and equivalents $141.2M at Dec 31, 2024; Q4 net loss $12.4M vs $7.9M year ago.
- APEX Phase 2 trial topline results expected in 2026; Phase 1b Part B results expected 2H'25.
- TX2100 Phase 1 initiation expected Q4'25 or Q1'26 for hereditary hemorrhagic telangiectasia.

## SEC filing metadata
- accession: 0000950170-25-042630
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000095017025042630/0000950170-25-042630-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000095017025042630/tecx-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-042630
- JSON: https://secwatch.observer/filing/0000950170-25-042630.json
- Plain text: https://secwatch.observer/filing/0000950170-25-042630.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.